Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Annals of Hematology|December 6, 2006
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicinSuzanne E Biehn, Dominic T Moore, Peter M Voorhees, et al.
Leukemia Research|June 24, 2019
Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myelomaParameswaran Hari, Claudia E Paba-Prada, Peter M Voorhees, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2025
Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM)Cindy Varga, Kip D Zimmerman, David M Foureau, et al.
Life (Basel, Switzerland)|March 28, 2024
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)Hamid Ehsan, Myra Robinson, Peter M Voorhees, et al.
Oncotarget|September 2, 2015
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman diseaseFrits van Rhee, Corey Casper, Peter M Voorhees, et al.
British Journal of Haematology|January 6, 2021
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1Sara Bringhen, Peter M Voorhees, Torben Plesner, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2023
Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study)Hamid Ehsan, Alec Britt, Peter M Voorhees, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2021
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025Peter M Voorhees, Andrzej J Jakubowiak, Shaji K Kumar, et al.
BMC Cancer|November 11, 2020
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myelomaRafael Fonseca, Saad Z Usmani, Maneesha Mehra, et al.
Leukemia & Lymphoma|December 14, 2011
A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemiaMatthew C Foster, Chirag Amin, Peter M Voorhees, et al.
Pageof 10